Head-to-head · WeighScore
Mojoon vs WeightCare
By GLP-1 ScorecardUpdated
Score comparison
Mojoon has the higher recorded score — 52.9/100 to 52.2/100, but only just.
Mojoon grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Premium-priced telehealth provider offering compounded semaglutide. WeightCare is close behind and may still be the better fit — see the factor split below.
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.
The numbers
Swipe or scroll to compare both providers.
| Metric | Mojoon | WeightCare |
|---|---|---|
| WeighScore | 52.9/100 | 52.2/100 |
| Grade | C | C |
| Site position | #517 | #522 |
| Semaglutide | $450/mo (starting dose, compounded) | $399/mo |
| Tirzepatide | Not disclosed | $499/mo (15 mg dose, compounded) |
| Coverage | Coverage not published | Coverage not published |
| Brand-name access | Not confirmed | Not confirmed |
| Oral / sublingual | Not confirmed | Not confirmed |
Site position #517 · C
Strengths
- Both semaglutide and tirzepatide available
- Compounded GLP-1 access
What to consider
- Premium pricing relative to market
Site position #522 · C
FDAWarning letter issued to Weightless Medical LLC dba WeightCare in February 2026. See the FDA warning-letter database.
Strengths
- PCAB-accredited pharmacy partners — strongest pharmacy quality signal
- Quality testing: potency and sterility per USP 797 standards
- 85,000+ members since 2022 — established patient base
- Multiple program tiers for semaglutide
- Health coaching, dietitians, fitness trainers included
What to consider
- No LegitScript certification on the site itself
- State availability not explicitly listed
- Compounded only — no brand-name options
- Semaglutide runs $215-$399/mo and tirzepatide $275-$499/mo depending on plan length and dose
- FDA issued Weightless Medical LLC dba WeightCare a warning letter in February 2026; the letter is public in FDA's warning-letter database
Featured provider
CoreAge Rx
CoreAge Rx scores 89.5/100 (B+). Advertises pricing across doses with no membership fee, but starting-price displays and FAQ payment/refund promises need to be reconciled with the selected plan and refund policy.
Commercial relationships affect this placement. The score comparison above is separate.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.